Abstract
In an attempt to examine whether the inactivation of p16INK4a is an important early event in the development of sporadic melanoma in vivo, we have systematically analysed 46 uncultured primary cutaneous melanomas. Loss of heterozygosity (LOH) of chromosome region 9p21-22 (where the p16INK4a resides) was detected in 11 tumours (24%) by PCR-based LOH analyses. Direct sequencing of all three exons of the p16INK4a gene in these 11 tumours revealed no somatic mutation although germline mutations which have not been reported previously as common polymorphisms were detected in two patients. Further sequencing analyses of the p16INK4a gene exon 2 in 19 additional tumours with no evidence of LOH on 9p21-22 identified only one heterozygous C – >T mutation at codon 81 altering a proline to a leucine. A sensitive methylation-specific PCR assay did not reveal de novo methylation of the 5′CpG island in exon 1 of the p16INK4a gene in any of the tumours showing 9p21-22 allelic loss or a heterozygous p16INK4a mutation. Complete loss of p16INK4a protein, most likely due to homozygous deletion of the p16INK4a gene, was observed in 6 (15%) out of 39 evaluable cases by immunohistochemical analyses on frozen sections using two different anti-p16INK4a antibodies. The results show that inactivation of p16INK4a is not as frequent in primary melanoma as has been reported in cell lines, and warrant further search for another tumour suppressor on 9p21-22. This study also emphasizes the importance of examining uncultured primary tumours rather than cell lines to define early events in tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Biden K, Young J, Buttenshaw R, Searle J, Cooksley G, Xu DB and Leggett B. . 1997 Hepatology 25: 593–597.
Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D and Sidransky D. . 1995 Nat. Genet. 11: 210–212.
Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG and Hayward NK. . 1997 Cancer Res. 57: 4868–4875.
El-Naggar AK, Lai S, Clayman G, Lee J-KJ, Luna MA, Goepfert H and Batsakis JG. . 1997 Am. J. Pathol. 151: 1767–1774.
Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS and Clayton RN. . 1997 Cancer Res. 57: 2703–2709.
Flores JF, Walker GJ, Glendening JM, Haluska FG, Castresana JS, Rubio MP, Pastorfide GC, Boyer LA, Kao WH, Bulyk ML, Barnhill RL, Hayward NK, Housman DE and Fountain JW. . 1996 Cancer Res. 56: 5023–5032.
Foulkes WD, Flanders TY, Pollock PM and Hayward NK. . 1997 Mol. Med. 3: 5–20.
Fountain JW, Bale SJ, Housman DE and Dracopoli NC. . 1990 Cancer Surv. 9: 645–671.
Fountain JW, Karayioorgou M, Ernstoff MS, Kirkwood JM, Vlock DR, Titus-Ernstoff L, Bouchard B, Vijayasaaradhi S, Houghton AN, Lahti J, Kidd VJ, Housman DE and Dracopoli NC. . 1992 Proc. Natl. Acad Sci. USA 89: 10557–10561.
Gazzeri S, Gouyer V, Vour'ch C, Brambilla C, Brambilla E. . 1998 Oncogene 16: 497–504.
Gonzalez ZM, Bender CM, Yang AS, Nguyen T, Beart RW, Van TJ and Jones PA. . 1995 Cancer Res. 55: 4531–4535.
Gonzalgo ML, Bender CM, You EH, Glendening LM, Flores JF, Walker GJ, Hayward NK, Jones PA and Fountain JW. . 1997 Cancer Res. 57: 5336–5347.
Gyapay G, Morissette J, Vignal A, Dib C, Fizames C, Millasseau P, Marc S, Bernardi G, Lathrop M and Weissenbach J. . 1994 Nature Genet. 7: 246–339.
Healy E, Rehman I, Angus B and Rees JL. . 1995 Genes Chrom. Cancer 12: 152–156.
Healy E, Belgaid CE, Takata M, Vahlquist A, Rehman I, Rigby H and Rees JL. . 1996a Cancer Res. 56: 589–593.
Healy E, Sikkink S and Rees JL. . 1996b J. Invest. Dermatol. 107: 318–321.
Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB. . 1995 Cancer Res. 55: 4525–4530.
Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB. . 1996 Proc. Natl. Acad Sci. USA 93: 9821–9826.
Holland EA, Beaton SC, Edwards BG, Kefford RF and Mann GJ. . 1994 Oncogene 9: 1361–1365.
Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WJ, Tucker MA and Dracopoli NC. . 1994 Nat. Genet. 8: 15–21.
Isshiki K, Seng BA, Elder DE, Guerry D and Linnenbach AJ. . 1994 Oncogene 9: 1649–1653.
Kageshita T, Nakamura T, Yamada M, Kuriya N, Arao T and Ferrone S. . 1991 Cancer Res. 51: 1726–1732.
Kamb A, Gruis NA, Weaver FJ, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RR, Johnson BE and Skolnick MH. . 1994a Science 264: 436–440.
Kamb A, Shattuck ED, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Fjand J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolinick MH, and Cannon-Albright LA. . 1994b Nat. Genet. 8: 23–26.
Kim SK, Ro JY, Kemp BL, Lee JS, Kwon TJ, Fong KM, Sekido Y, Minna JD, Hong WK and Mao L. . 1997 Cancer Res. 57: 400–403.
Kinoshita I, Dosaka AH, Mishina T, Akie K, Nishi M, Hiroumi H, Hommura F and Kawakami Y. . 1996 Cancer Res. 56: 5557–5562.
Krementz ET, Reed RJ, Coleman WPI, Sutherland CM, Carter RD and Campbell M. . 1982 Ann. Surg. 195: 632–645.
Liu Q, Neuhausen S, McClure M, Frye C, Weaver-Feldhaus J, Gruis NA, Eddington K, Allalunis TM, Skolnick MH, Fujimura FK and Kamb A. . 1995 Oncogene 10: 1061–1067.
Marchini S, Aodegoni AM, Bonazzi C, Chiari S and Broggini M. . 1997 Br. J. Cancer 76: 146–149.
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB and Sidransky D. . 1995 Nat. Med. 1: 686–692.
Morita R, Fujimoto A, Hatta N, Takehara K and Takata M. . 1998 J. Invest. Dermatol. 111: 919–924.
Myöhänen SK, Baylin SB and Herman JG. . 1998 Cancer Res. 58: 591–593.
Nakagawa K, Conrad NK, Williams JP, Johnson BE and Kelley MJ. . 1995 Oncogene 11: 1843–1851.
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K and Carson DA. . 1994 Nature 368: 753–756.
Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM and Huebner K. . 1994 Cancer Res. 54: 5269–5272.
Ohta M, Berd D, Shimizu M, Nagai H, Cotticelli MG, Mastrangelo M, Shields JA, Shields CL, Croce CM and Huebner K. . 1996 Int. J. Cancer 65: 762–767.
Pollock PM, Yu F, Qiu L, Parsons PG and Hayward NK. . 1995 Oncogene 11: 663–668.
Puig S, Ruiz A, Lazaro C, Castel T, Lynch M, Palou J, Vilalta A, Weissenbach J, Mascaro JM and Estivill X. . 1995 Am. J. Hum. Genet. 57: 395–402.
Reed JA, Loganzo FJ, Shea CR, Walker GJ, Flores JF, Glendening JM, Bogdany JK, Shiel MJ, Haluska FG, Fountain JW and Albino AP. . 1995 Cancer Res. 55: 2713–2718.
Schmidt EE, Ichimura K, Messerle KR, Goike HM and Collins VP. . 1997 Br. J. Cancer 75: 2–8.
Seiji M, Mihm MC, Sober AJ, Takahashi M, Kato T and Fitzpatrick TB. . 1979 Pigment Cell 5: 95–104.
Shih YC, Kerr J, Liu J, Hurst T, Khoo SK, Ward B, Wainwright B and Chenevix TG. . 1997 Int. J. Cancer 70: 508–511.
Smith SB and Hovig E. . 1996 Hum. Mutat. 7: 294–303.
Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, Parsons PG and Hayward NK. . 1994 Int. J. Cancer 58: 203–206.
Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID and Fountain JW. . 1998 Genes Chrom. Cancer 22: 157–163.
Weaver-Feldhaus J, Gruis NA, Neuhausen S, Le PD, Stockert E, Skolnick MH and Kamb A. . 1994 Proc. Natl. Acad Sci. USA 91: 7563–7567.
Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, Rao K, Drabkin H, Gemmill R, Ahrent S, Sidransky D, Saccomanno G, Fountain JW and Anderson MW. . 1997 Cancer Res. 57: 1–6.
Acknowledgements
The authors are grateful to Professor Jonathan Rees and Dr Eugene Healy (University of Newcastle Upon Tyne, UK) for critical reading of the manuscript. We also thank Kanako Yasuyoshi and Yuko Yamada for their excellent technical help in gel electrophoresis and immunohistochemistry. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Science, Education and Culture of Japan (09670868), and grants from Shiseido Foundation and Lydia O'Leary Memorial Foundation.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fujimoto, A., Morita, R., Hatta, N. et al. p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 18, 2527–2532 (1999). https://doi.org/10.1038/sj.onc.1202803
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202803
Keywords
This article is cited by
-
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Clinical Epigenetics (2017)
-
Epigenetic Inactivation of Tumor Suppressor Genes in Serum of Patients with Cutaneous Melanoma
Journal of Investigative Dermatology (2006)
-
Early cancers of the skin: clinical, histopathological, and molecular characteristics
International Journal of Clinical Oncology (2005)
-
The genetics of malignant melanoma: lessons from mouse and man
Nature Reviews Cancer (2003)